Abstract
The canine metabolic diseases, such as obesity and diabetes, have become a worldwide problem. Fibroblast growth factor 21 (FGF21) is a potent regulator which has many biological functions relative to metabolism regulation. It suggests that FGF21 plays important roles in regulating canine metabolic diseases. To acquire the recombinant canine FGF21 (rcFGF21) in Escherichia coli, the recombinant bacteria were induced by 0.5 mM IPTG for 16 hours at 16 °C, and the rcFGF21 protein was purified by Ni-NTA. 8 mg rcFGF21 was acquired from one liter bacteria. The rcFGF21 protein has specific immunoblot reactivity against anti-FGF21 and anti-His antibody. The in vivo experimental result showed that rcFGF21 can significantly reduce plasma glucose of STZ-induced diabetic mice.
Keywords: Recombinant canine FGF21, Escherichia coli, purification, plasma glucose.
Protein & Peptide Letters
Title:Expression, Purification and Characterization of Recombinant Canine FGF21 in Escherichia coli
Volume: 23 Issue: 9
Author(s): Zhong Zhenga, Chengjun Yanga, Ruofeng Yinb, Jinxi Jiangc, Haiting Hea, Xinxin Wanga, Mujie Kan and Yechen Xiao
Affiliation:
Keywords: Recombinant canine FGF21, Escherichia coli, purification, plasma glucose.
Abstract: The canine metabolic diseases, such as obesity and diabetes, have become a worldwide problem. Fibroblast growth factor 21 (FGF21) is a potent regulator which has many biological functions relative to metabolism regulation. It suggests that FGF21 plays important roles in regulating canine metabolic diseases. To acquire the recombinant canine FGF21 (rcFGF21) in Escherichia coli, the recombinant bacteria were induced by 0.5 mM IPTG for 16 hours at 16 °C, and the rcFGF21 protein was purified by Ni-NTA. 8 mg rcFGF21 was acquired from one liter bacteria. The rcFGF21 protein has specific immunoblot reactivity against anti-FGF21 and anti-His antibody. The in vivo experimental result showed that rcFGF21 can significantly reduce plasma glucose of STZ-induced diabetic mice.
Export Options
About this article
Cite this article as:
Zhenga Zhong, Yanga Chengjun, Yinb Ruofeng, Jiangc Jinxi, Hea Haiting, Wanga Xinxin, Kan Mujie and Xiao Yechen, Expression, Purification and Characterization of Recombinant Canine FGF21 in Escherichia coli, Protein & Peptide Letters 2016; 23 (9) . https://dx.doi.org/10.2174/0929866523666160628091657
DOI https://dx.doi.org/10.2174/0929866523666160628091657 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Central Sympathetic Nervous System: A New Target for Cardioprotective Drugs
Drug Design Reviews - Online (Discontinued) Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Renal and Urological Diseases of the Newborn Neonatal Acute Kidney Injury
Current Pediatric Reviews Impact of Exercise Training on Physiological Measures of Physical Fitness in the Elderly
Current Aging Science Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and Molecular Aspects
Current Pharmaceutical Design Collagen Cross-link Breakers:A Beginning of a New Era in the Treatment of Cardiovascular Changes Associated with Aging,Diabetes,and Hypertension
Current Drug Targets - Cardiovascular & Hematological Disorders Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Sulfonated Carbon/Silica Composites: Highly Efficient Heterogeneous Catalysts for the One-Pot Synthesis of Hantzsch 1,4-dihydropyridines, 2,4,5-trisubstituted Imidazoles and 2-arylbenzimidazoles
Current Catalysis Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Moderate Hypothermia in the Management of Severe Traumatic Brain Injury: A Good Idea Proved Ineffective?
Current Pharmaceutical Design Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets